07 Oct 2026, 15:25 IST
IPCA Laboratories Limited
HDFC Securities · BUY · target Rs 2,010
The report expects 11% YoY revenue growth with gross margin expansion supporting EBITDA margin improvement.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.